31 results about "Viral meningitis" patented technology

The invention belongs to the field of medicaments, discloses application of lycorine, lycorine salt, lycorine hydrate, lycorine optical isomer or lycorine prodrug in preparing medicaments for treating diseases caused by human enterovirus 71 type infection, preferably treating hand-foot-and-mouth disease, herpangina, viral meningitis, viral encephalitis, flaccid paralysis, pulmonary edema and vital myocarditis. In vitro and in vivo tests prove that the lycorine can inhibit replication and lesion of enterovirus (EV) 71 in cells, has excellent function of inhibiting the EV 71 virus, and has clinical application prospect.

The invention relates to a medicament for treating viral meningitis, in particular to a traditional Chinese medicine composition for treating viral meningitis, which is prepared from plant Chinese herbal medicines as raw materials. The medicament is characterized in that the raw materials for preparing active constituents comprise the following components of: 20-30 g of raw Astragalus mongholicus, 20-30 g of indigo naturalis, 10-20 g of red ginseng, 10-20 g of white paeony roots, 5-15 g of bighead atractylodes rhizome, 5-15 g of bamboo shavings, 5-15 g of bugbane, 5-15 g of the root of Chinese thorowax, 3-8 g of Pinellia ternate, 3-8 g of goldthread and 3-8 g of radix glycyrrhizae preparata. After being compounded, all raw materials bring out the best in each other so that the medicament has the effects of reinforcing Qi and raising Yang, regulating and nourishing spleens and stomachs, nourishing lungs to intensify exterior, reinforcing vital energy, treating blood disorders, activating blood and dissolving stasis, clearing heat and drying damp as well as purging intense heat and the like with the synergistic effect of a medicine effect, can treat both principal and secondary aspects of a disease without side effects, and has an obvious curative effect on viral meningitis caused by spleen and stomach Qi deficiency, sinking of middle Qi, deficient fire ascent and the like.

The invention discloses a PCT (Procalcitonin) and CRP (C-Reactive Protein) double-label time resolution fluorescence immunoassay method for simultaneously detecting bacterial meningitis and viral meningitis. A recombinant polypeptide antigen is included and the amino acid sequence is shown as SEQ ID NO: 1. The recombinant polypeptide antigen is used as an immunogen, and a PCT antibody and a CRP antibody are obtained by screening respectively through immune treatment; double-label time resolution fluorescence immunoassay is carried out. The method disclosed by the invention is high in sensitivity, is rapid, is simple and convenient and is easy to popularize clinically. The whole detection time of a kit utilizing the method is less than 2 hours, and suspected patients with the meningitis can be rapidly screened at an early stage. Reliable evidences are provided for specific treatment of children with the meningitis; pains of the children with the meningitis are alleviated and the diagnosis time of diseases is shortened; valuable time for the specific treatment is won, so that medical cost and a lot of manpower and material resource expenditures are saved, and worries and panics of parents are also alleviated.

The invention discloses an application of a system for detecting miRNA expression quantity to preparation of products for distinguishing tuberculous meningitis from viral meningitis. miRNA is four, orthree, or two or one of hsa-miR-126-3p, hsa-miR-130a-3p, hsa-miR-151a-3p and hsa-miR-199a-5p. The invention discloses an miRNA spectrum in peripheral blood mononuclear cells of patients suffering from tuberculous meningitis and viral, so that better understanding of the nosogenesis of the two diseases is facilitated, what's more, four miRNA for distinguishing or assisting in distinguishing the tuberculous meningitis from the viral meningitis can be obtained through identification, and the system has quite important significance in improvement of diagnosis of the tuberculous meningitis.

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

The invention discloses molecular markers for auxiliary clinical diagnosis of viral meningitis as well as application and a kit of the molecular markers. Firstly, systematic gene chip analysis is carried out on two groups of cerebrospinal fluid samples of viral meningitis and normal control by a miSeq high-throughput sequencing technology, differential miRNA expression is screened, the screened differential expression miRNA is further verified one by one by an RT-qPCR technology, and finally, it is found that miR-RNA 18_41385, hsa-miR-486-5p, hsa-miR-4497 and the hsa-miR-3178 can be used as specific markers for early auxiliary clinical diagnosis of the viral meningitis. The markers can also be used for differential diagnosis of other meningitis. The kit has the advantages of being good in stability, simple and convenient in detection method, high in sensitivity, specific and the like, achieves effective supplementation of an existing clinical viral meningitis diagnosis method and rapid definite diagnosis of viral meningitis patients, and is of great significance in reducing the death rate of the viral meningitis and improving the treatment effect and prognosis.

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The invention discloses a traditional Chinese medicine preparation for treating viral meningitis and a preparation method and application thereof. The traditional Chinese medicine preparation is prepared from, by mass, 65-80 parts of spanishneedles herb, 4-6 parts of indigo naturalis and 30-42 parts of bur beggarticks herb. The preparation method comprises the steps that spanishneedles herb and bur beggarticks herb are taken, mixed and smashed, an ethanol solution is added to the mixture, reflux extraction is conducted for three times, and obtained filtrates are mixed and then concentrated into extract; medicinal material dregs obtained after extraction is conducted are taken, water is added to the medicinal material dregs, boiling extraction is conducted for two times, and extracting solutions are mixed, filtered and then concentrated into thick paste; indigo naturalis is mixed with the extract and the thick paste, and the obtained mixture is prepared into powder. All the selected medicinal materials of the traditional Chinese medicine preparation are appropriate in compatibility, and the traditional Chinese medicine preparation accords with the theories of traditional Chinese medicine and pharmacy and modern medicine and pharmacology, has the effects of arresting convulsion, calming the nerves, activating the blood circulation, dispersing blood stasis, clearing heat, removing toxicity and eliminating dampness, has a unique therapeutic effect on treating diseases of the viral meningitis and the like and is significant in curative effect, low in cost, safe, reliable, free of any toxic and side effect, free of relapse after healing, capable of achieving the purposes of treating both symptoms and root causes and worthy of wide application and promotion in clinic.

The invention discloses an application of chebulagic acid in the preparation of a medicament for treating diseases resulted from a human enterovirus type 71 infection. Preferably, the diseases resulted from the human enterovirus type 71 infection comprise foot and mouth disease, herpangina, viral meningitis, viral encephalitis, flaccid paralysis, pulmonary edema or viral myocarditis. In-vivo and in-vitro experiments show that chebulagic acid can inhibit replication and lesions of the human enterovirus type 71 in cells, has a good therapeutic effect for the diseases resulted from the human enterovirus type 71 infection, and has a clinical application prospect.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The present disclosure relates to 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs capable of inhibiting viral infections and methods of using these compounds in the treatment of viral infections, the viral infections such as human immunodeficiency virus (HIV), human papilloma virus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), varicella, infectious mononuclear hyperplasia, parotitis, measles, rubella, herpes zoster, Ebola virus, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, and the like. Parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue fever (DENV), influenza, West Nile virus (WNV), zika virus (ZIKV), 229E, NL63, OC43, HKU1, Middle East Respiratory Syndrome Coronavivirus (MERS), severely acute respiratory Syndrome Coronavivirus (SERS), and severely acute respiratory Syndrome Coronavivirus (SERS) This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formula should be inserted here as it appears on the abstract in paper form. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.